By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Signal Genetics today said that it will use its MyPRS genomic testing platform in a multiple myeloma research program being conducted by Array BioPharma.

According to the New York-based firm, it will provide Array BioPharma with genetic information from patient samples in two upcoming clinical studies on an Array drug candidate. It said that the collaboration may lead to the development of "superior and personalized treatment options for myeloma patients."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.